Search

Your search keyword '"Pulmonary fibrosis -- Care and treatment -- Development and progression"' showing total 4 results
Start Over Descriptor "Pulmonary fibrosis -- Care and treatment -- Development and progression" Topic business
4 results on '"Pulmonary fibrosis -- Care and treatment -- Development and progression"'

1. United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Subjects
United Therapeutics Corp., Medical research, Medicine, Experimental, Pulmonary fibrosis -- Care and treatment -- Development and progression, Biotechnology industry, Treprostinil, Business, Business, international, Tyvaso (Medication)
Abstract

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half [...]

Published
2024

2. Boehringer Ingelheim's latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Subjects
Boehringer Ingelheim Pharmaceuticals Inc., Medical research, Medicine, Experimental, Respiratory agents, Pulmonary fibrosis -- Care and treatment -- Development and progression, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

- Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine - Potential new treatment for [...]

Published
2022

3. FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2

Subjects
FibroGen Inc., Medical research, Medicine, Experimental, Pulmonary fibrosis -- Care and treatment -- Development and progression, Biotechnology industry, Clinical trials, Banking, finance and accounting industries, Business
Abstract

SAN FRANCISCO, Dec 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- FibroGen, Inc. (NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab [...]

Published
2020

4. InterMune Canada Inc release: game changing therapy for idiopathic pulmonary fibrosis now available in Canada

Subjects
Respiratory tract diseases -- Care and treatment -- Development and progression, Pulmonary fibrosis -- Care and treatment -- Development and progression, Business, Chemicals, plastics and rubber industries
Abstract

Following Health Canada's market approval of Esbriet (pirfenidone) on 1 Oct 2012, InterMune Canada Inc has announced that the only treatment indicated for mild to moderate idiopathic pulmonary fibrosis (IPF) [...]

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results